TherapeuticsMD Inc Stock Research

Market Summary

USD3.45-0.20

Market Closed

-5.48%

TXMD Stock Price

TXMD RSI Chart

TXMD Valuation

Market Cap

32.7M

Price/Earnings (Trailing)

-3.77

Price/Sales (Trailing)

0.37

EV/EBITDA

2.56

Price/Free Cashflow

-0.32

TXMD Price/Sales (Trailing)

TXMD Profitability

EBT Margin

-9.57%

Return on Assets

-6.47%

Free Cashflow Yield

-316.67%

TXMD Fundamentals

TXMD Revenue

Revenue (TTM)

87.5M

Revenue Y/Y

-17.67%

Revenue Q/Q

-26.76%

TXMD Earnings

Earnings (TTM)

-8.7M

Earnings Y/Y

38.92%

Earnings Q/Q

-125.8%

Price Action

52 Week Range

1.9923.00

(Low)(High)

Last 7 days

-21.8%

Last 30 days

-27.1%

Last 90 days

-44.9%

Trailing 12 Months

-77.6%

TXMD Financial Health

Current Ratio

0.5

Debt/Cashflow

-1.1

TXMD Investor Care

Shares Dilution (1Y)

12.12%

Diluted EPS (TTM)

-1.43

Peers (Alternatives to TherapeuticsMD)

View All Peers In Detail

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
JNJ	404.8B	94.9B	-5.16%	-10.64%	22.56	4.26	1.25%	-14.07%
LLY	296.8B	28.5B	-5.67%	20.74%	47.53	10.4	0.79%	11.88%
MRK	272.8B	59.3B	-1.75%	40.02%	17.88	4.63	21.72%	11.27%
PFE	226.4B	100.3B	-8.43%	-20.95%	7.22	2.26	23.43%	42.74%
BMY	142.7B	46.2B	-7.78%	-1.12%	22.55	3.09	-0.49%	-9.54%
MID-CAP
PRGO	4.8B	4.5B	-0.20%	-5.41%	-34.17	1.08	7.56%	-104.06%
RETA	3.3B	2.2M	105.10%	171.03%	-10.52	1.5K	-80.71%	-4.88%
SMALL-CAP
SUPN	1.9B	667.2M	-9.96%	17.66%	31.57	2.87	15.09%	13.64%
TLRY	1.6B	602.5M	-17.77%	-52.80%	-2.74	2.63	18.18%	-18.59%
CGC	991.7M	478.9M	-11.35%	-65.42%	-0.32	2.07	-31.50%	-634.70%
INVA	792.9M	285.2M	-7.22%	-37.95%	3.6	2.78	-27.21%	-40.28%
CRON	768.8M	114.5M	-15.28%	-37.42%	-4.56	6.72	27.90%	57.40%
PAHC	612.8M	972.1M	-6.94%	-26.30%	16.32	0.63	10.54%	-19.02%
OPNT	106.7M	-	2.08%	-28.79%	-3.22	2.72	4.98%	-2206.89%
TXMD	32.7M	87.5M	-27.15%	-77.57%	-3.77	0.37	-3.70%	94.95%

Financials for TherapeuticsMD

Income Statement (Last 12 Months)
Description	(%) Q/Q	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3
Revenue	-4.9%	87,489,000	91,978,000	86,418,000	86,951,000	90,851,000
Gross Profit	-4.1%	69,364,000	72,359,000	67,407,000	68,113,000	71,169,000
Operating Expenses	-11.5%	170,573,000	192,742,000	204,128,000	207,883,000	210,154,000
S&GA Expenses	-11.5%	83,705,000	94,581,000	103,066,000	108,195,000	112,189,000
R&D Expenses	-8.2%	5,512,000	6,005,000	6,436,000	7,086,000	8,060,000
EBITDA	82.5%	34,325,000	18,810,000	-142,449,000	-135,405,000	-
EBITDA Margin	91.8%	0.39	0.20	-1.65	-1.56	-
Earnings Before Taxes	68.5%	-8,375,000	-26,570,000	-182,053,000	-172,415,000	-171,542,000
EBT Margin	66.9%	-0.10	-0.29	-2.11	-1.98	-
Interest Expenses	-6.5%	38,517,000	41,202,000	37,102,000	32,917,000	32,953,000
Net Income	68.0%	-8,665,000	-27,120,000	-182,053,000	-172,415,000	-171,542,000
Net Income Margin	66.4%	-0.10	-0.29	-2.11	-1.98	-
Free Cahsflow	15.7%	-103,429,000	-122,661,000	-133,852,000	-142,727,000	-

* denotes actual numbers (not divided by Millions)
Balance Sheet					(In Millions)
Description	(%) Q/Q	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3
Assets	-8.4%	134	146	133	169	210
Current Assets	-11.3%	87.00	99.00	84.00	119	160
Cash Equivalents	2.1%	38.00	38.00	30.00	65.00	105
Inventory	9.0%	7.00	6.00	9.00	8.00	7.00
Net PPE	-22.4%	1.00	1.00	1.00	1.00	1.00
Liabilities	5.8%	182	172	274	263	267
Current Liabilities	6.1%	174	164	265	253	86.00
Long Term Debt	3.1%	94.00	91.00	203	188	187
LT Debt, Current	3.1%	94.00	91.00	203	188	15.00
LT Debt, Non Current	-100.0%	-	172	-	-	-
Retained Earnings	-2.9%	-1,017	-988	-1,100	-1,051	-1,008
Additional Paid-In Capital	0.7%	969	962	960	958	951
Shares Outstanding	6.9%	9.00	9.00	9.00	9.00	8.00

Cashflow (Last 12 Months)					(In Thousands)
Description	(%) Q/Q	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3
Cashflow From Operations	15.7%	-103,408	-122,711	-133,839	-142,693	-133,492
Share Based Compensation	-17.7%	13,933	16,939	17,230	18,125	14,956
Cashflow From Investing	0.1%	140,802	140,651	-1,997	-2,223	-1,203
Cashflow From Financing	-13.2%	-103,905	-91,811	28,603	129,552	159,902

Risks for TXMD

What is the probability of a big loss on TXMD?

100%

Probability that TherapeuticsMD stock will be more than 20% underwater in next one year

97.7%

Probability that TherapeuticsMD stock will be more than 30% underwater in next one year.

86.5%

Probability that TherapeuticsMD stock will be more than 40% underwater in next one year.

*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does TXMD drawdown profile look like?

Y-axis is the maximum loss one would have experienced if TherapeuticsMD was unfortunately bought at previous high price.

Drawdowns

Returns for TXMD

Cumulative Returns on TXMD

-27.0%

10-Year Cumulative Returns

-47.0%

7-Year Cumulative Returns

-57.5%

5-Year Cumulative Returns

-63.4%

3-Year Cumulative Returns

What are the long-term rolling returns for TXMD?

FIve years rolling returns for TherapeuticsMD.

Annualized Returns

Which funds bought or sold TXMD recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
2023-02-21	NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO	unchanged	-	-212	788	-%
2023-02-16	HARBOUR INVESTMENTS, INC.	unchanged	-	45.00	45.00	-%
2023-02-15	Tejara Capital Ltd	new	-	1,773,780	1,773,780	1.02%
2023-02-15	Steward Partners Investment Advisory, LLC	unchanged	-	73.00	73.00	-%
2023-02-15	Financial Gravity Asset Management, Inc.	new	-	1.00	1.00	-%
2023-02-15	State of Wyoming	sold off	-100	-58,000	-	-%
2023-02-15	HOWE & RUSLING INC	sold off	-100	-	-	-%
2023-02-14	AMERIPRISE FINANCIAL INC	reduced	-0.04	-23,000	126,000	-%
2023-02-14	MONEY CONCEPTS CAPITAL CORP	new	-	39.00	39.00	-%
2023-02-14	STATE STREET CORP	new	-	148,303	148,303	-%

Latest Funds Activity

Are funds buying TXMD calls or puts?

Calls

Puts

Are funds bullish or bearish(Calls - Puts)?

Net Call Options

No. of funds that own TXMD

No. of Funds

TherapeuticsMD News

Schedule 13G FIlings of TherapeuticsMD

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Aug 30, 2022	rubric capital management lp	18.27%	1,721,953	SC 13D/A
Jul 08, 2022	blackrock inc.	1.4%	122,138	SC 13G/A
Jun 03, 2022	beryl capital management llc	1.5%	126,229	SC 13G
Mar 23, 2022	smith robert j	5.38%	23,103,292	SC 13D/A
Feb 14, 2022	price t rowe associates inc /md/	0.1%	649,807	SC 13G/A
Feb 01, 2022	blackrock inc.	5.9%	24,894,812	SC 13G/A
Jul 07, 2021	flynn james e	4.90%	20,662,810	SC 13G
Feb 16, 2021	price t rowe associates inc /md/	6.2%	18,869,212	SC 13G/A
Feb 10, 2021	vanguard group inc	4.39%	13,165,644	SC 13G/A
Feb 08, 2021	fmr llc	-	0	SC 13G/A

TXMD Fair Value

TherapeuticsMD fair value in different scenarios

The table shows the Fair Value estimates for TherapeuticsMD for various scenarios. Disclaimer: These are just estimations from a model. None of the models are good at predicting the future. Please dont buy or sell stocks based on these outputs.

Fair Value	Very Pessimistic	Pessimistic	Base Case	Optimistic	Very Optimistic
Very Low Inflation	- -	- -	1.02 -70.43%	7.32 112.17%	17.18 397.97%
Current Inflation	- -	- -	0.38 -88.99%	5.84 69.28%	14.34 315.65%
Very High Inflation	- -	- -	- -	4.09 18.55%	11.00 218.84%

Historical TherapeuticsMD Fair Value Estimates

Very Pessimistic Case

Pessimistic Case

Fair Value

Optimistic Case

Very Optimistic Case

Closing Stock Price

Recent SEC filings of TherapeuticsMD

View All Filings

Date Filed	Form Type	Document
Feb 27, 2023	8-K	Current Report
Feb 23, 2023	4	Insider Trading
Feb 23, 2023	4	Insider Trading
Feb 22, 2023	4/A	Insider Trading
Feb 13, 2023	5	Insider Trading
Jan 30, 2023	4	Insider Trading
Jan 25, 2023	4	Insider Trading
Jan 18, 2023	8-K	Current Report
Jan 12, 2023	8-K	Current Report
Jan 06, 2023	8-K/A	Current Report

Latest Insider Trading transactions for TXMD

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
2023-01-27	Donegan Michael C	sold	-249	5.09	-49.00	prin. fin. and acctg. officer
2023-01-26	Donegan Michael C	acquired	-	-	5,940	prin. fin. and acctg. officer
2023-01-26	Donegan Michael C	sold	-8,371	5.0796	-1,648	prin. fin. and acctg. officer
2023-01-24	Donegan Michael C	sold	-37.1707	5.3101	-7.00	prin. fin. and acctg. officer
2023-01-23	Donegan Michael C	sold	-6,950	5.3383	-1,302	prin. fin. and acctg. officer
2023-01-23	Donegan Michael C	acquired	-	-	4,365	prin. fin. and acctg. officer
2022-12-30	Rubric Capital Management LP	sold	-38,657,000	1,333	-29,000	-
2022-12-30	Rubric Capital Management LP	back to issuer	-38,657,000	1,333	-29,000	-
2022-12-09	Rubric Capital Management LP	bought	90,284	6.09	14,825	-
2022-12-09	Bernick Brian	sold	-2,019	6.3121	-320	co-chief executive officer

About TherapeuticsMD

Hugh O'Dowd

www.therapeuticsmd.com

420

TherapeuticsMD, Inc. operates as a women's healthcare company in the United States. The company offers IMVEXXY for the treatment of moderate-to-severe dyspareunia; BIJUVA, a bio-identical hormone therapy combination of 17ÃƒÅ¸-estradiol and progesterone for the treatment of moderate-to-severe vasomotor symptoms; and ANNOVERA, a ring-shaped contraceptive vaginal system. Its preclinical projects include the development of TX-005HR, a progesterone-alone transdermal cream; TX-006HR, an estradiol and progesterone transdermal cream; TX-007HR and TX-008HR, which are transdermal patch product candidates; and TX-009HR, an oral progesterone and estradiol formulation. It also manufactures and distributes branded and generic prescription prenatal vitamins under the vitaTrue, vitaPearl, vitaMedMD, and BocaGreenMD Prena1 brands. The company sells its prescription pharmaceutical products and prenatal vitamin products to wholesale distributors and retail pharmacy distributors. TherapeuticsMD, Inc. was founded in 2008 and is headquartered in Boca Raton, Florida.

TXMD Income Statement

2022-09-30

CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) shares in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Total revenue, net	$ 20,917,000	$ 25,406,000	$ 68,811,000	$ 68,273,000
Cost of goods sold	3,788,000	5,282,000	13,388,000	14,101,000
Total gross profit	17,129,000	20,124,000	55,423,000	54,172,000
Operating expenses:
Selling and marketing	19,129,000	30,005,000	61,703,000	86,193,000
General and administrative	17,635,000	28,435,000	55,445,000	66,691,000
Research and development	1,112,000	1,605,000	4,092,000	5,666,000
Total operating expenses	37,876,000	60,045,000	121,240,000	158,550,000
Loss from operations	(20,747,000)	(39,921,000)	(65,817,000)	(104,378,000)
Other (expense) income:
Gain on sale of business			143,384,000
Expense for accretion of Mandatory Redeemable Preferred Stock	(3,457,000)		(3,457,000)
Fair value loss on Lender Warrants derivative liability	(76,000)		(76,000)
Loss on extinguishment of debt			(8,380,000)
Interest expense and other financing costs	(4,833,000)	(7,518,000)	(30,941,000)	(25,341,000)
Other (expense) income, net	(112,000)	19,000	(128,000)	264,000
Total other (expense) income, net	(8,478,000)	(7,499,000)	100,402,000	(25,077,000)
(Loss) income before income taxes	(29,225,000)	(47,420,000)	34,585,000	(129,455,000)
(Benefit) provision for income taxes	(260,000)	0	290,000	0
Net (loss) income	$ (28,965,000)	$ (47,420,000)	$ 34,295,000	$ (129,455,000)
(Loss) earnings per common share, basic	$ (3.13)	$ (5.62)	$ 3.86	$ (16.68)
Weighted average common shares, basic	9,261	8,444	8,877	7,762
(Loss) earnings per common share, diluted	$ (3.13)	$ (5.62)	$ 3.73	$ (16.68)
Weighted average common shares, diluted	9,261	8,444	9,205	7,762
Comprehensive (loss) income:
Net (loss) income	$ (28,965,000)	$ (47,420,000)	$ 34,295,000	$ (129,455,000)
Comprehensive (loss) income	(28,965,000)	(47,420,000)	34,295,000	(129,455,000)
Product [Member]
Total revenue, net	$ 20,917,000	24,456,000	68,327,000	67,039,000
License and Service [Member]
Total revenue, net		$ 950,000	$ 484,000	$ 1,234,000

TXMD Balance Sheet

2022-09-30

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Current assets:
Cash	$ 27,080	$ 65,122
Restricted cash	11,250
Accounts receivable, net of allowance for credit losses of $1,621 and $1,334 as of September 30, 2022 and December 31, 2021, respectively	32,157	36,176
Inventory	6,701	7,622
Prepaid and other current assets	10,290	10,548
Total current assets	87,478	119,468
Fixed assets, net	551	1,199
License rights and other intangible assets, net	37,876	40,318
Right of use assets	7,749	8,234
Other non-current assets	253	253
Total assets	133,907	169,472
Current liabilities:
Debt, net	93,602	188,269
Lender Warrants derivative liability	2,058
Make-whole payment derivative liability	1,751
Mandatory Redeemable Preferred Stock	19,709
Accounts payable	13,383	20,318
Accrued expenses and other current liabilities	43,568	44,304
Total current liabilities	174,071	252,891
Operating lease liabilities	7,553	8,063
Other non-current liabilities	554	2,139
Total liabilities	182,178	263,093
Commitments and contingencies (Note 9)
Stockholders' deficit:
Preferred stock, par value $0.001; 10,000 shares authorized, 22 issued and included in liabilities due to their redemption provisions
Common stock, par value $0.001; 12,000 shares authorized, 9,467 and 8,598 (adjusted for the 50-for-1 reverse stock split) shares issued and outstanding as of September 30, 2022 and December 31, 2021, respectively	9	9
Additional paid-in capital	968,785	957,730
Accumulated deficit	(1,017,065)	(1,051,360)
Total stockholders' deficit	(48,271)	(93,621)
Total liabilities and stockholders' deficit	$ 133,907	$ 169,472